---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342402"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2026-08-10T20:12:21+00:00"
generated_at: "2026-08-10T20:14:23.786645+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q2 2026: cash $243.2M, net loss $40.4M; NKX019 trials advance

## Summary
- Cash, equivalents, restricted cash and investments $243.2M as of June 30, 2026; expected to fund operations into 2029.
- Q2 2026 net loss $40.4M ($0.54 per share); R&D expense $29.0M, G&A expense $14.1M.
- Enrollment continues across Ntrust-1 and Ntrust-2 at 4B cells/dose (12B total) in all autoimmune indications.
- Outpatient dosing underway at community sites after FDA agreement; initial Ntrust data expected at 2026 medical conference.

## SEC filing metadata
- accession: 0001193125-26-342402
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2026-08-10T20:12:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000119312526342402/0001193125-26-342402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000119312526342402/nktx-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342402
- JSON: https://secwatch.observer/filing/0001193125-26-342402.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.